c-Met-IN-2 (Compound 14) also shows weak activity on other kinases, with IC50s of 731 nM (RON), 1075 nM (AxI), 18364 nM (VEGFR2), 2357 nM (PDGFRa), 5396 nM (c-Kit), 17056 nM (c-Src).

In mice bearing H1993 tumors, c-Met-IN-2 (0.1, 1, 10 mg/kg, p.o., once daily) significantly reduces the volume of tumors. c-Met-IN-2 has a similar effect in SNU-5 xenograft model via oral administration at 0.3, 1 and 3 mg/kg.